8-K: Salarius Amends Merger Terms, Sets Preferred Stock Conversion Floor

Salarius Pharmaceuticals modified its merger agreement with Decoy Therapeutics, adjusting preferred stock conversion terms with a new baseline price and a $3.75 per share floor for dilutive financings.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) entered into a Fifth Amendment to its Agreement and Plan of Merger with Decoy Therapeutics Inc. on September 17, 2025.
• The amendment modifies the conversion terms for Series A and Series B Non-Voting Convertible Preferred Stock.
• A new baseline assumed conversion price, the "Initial Issuance Price," is set at $10.50 per share for calculating proportional adjustments in subsequent dilutive financings.
• A floor price of $3.75 per share is established as the lowest price to be used in the calculation of price protection triggered by a Subsequent Financing.
• The redemption price for Series B Preferred Stock is changed to the Initial Issuance Price multiplied by 1,000, equating to $10,500 per share.
• Series B Preferred Stock is subject to mandatory redemption using 50% of net proceeds from the company's ATM Program or ELOC, and optional redemption by the company after the merger closing.
• Both Series A and Series B Preferred Stock have a conversion ratio of 1,000 shares of Common Stock per preferred share, subject to adjustments and certain conditions like stockholder approval and Nasdaq listing.

Sentiment

Score: 6

Explanation: The filing clarifies and formalizes terms of the merger agreement and preferred stock, which is a positive for transparency and certainty. However, the introduction of a floor price for anti-dilution protection could be seen as a slight negative for preferred shareholders, limiting their full downside protection. Overall, it's a neutral to slightly positive development as it moves the merger process forward with defined terms.

Positives

• Clarifies conversion terms and price protection mechanisms for preferred stockholders.
• Establishes a clear baseline "Initial Issuance Price" of $10.50 per share for future dilutive financing adjustments.
• Provides a defined redemption price for Series B Preferred Stock at $10,500 per share, offering clarity to holders.

Negatives

• The introduction of a $3.75 per share floor price for dilutive financing adjustments limits the downside protection for preferred stockholders compared to an uncapped anti-dilution provision.
• The "Initial Issuance Price" of $10.50 per share is a baseline assumed conversion price for calculation, not necessarily the current market price, which could be lower.

Risks

• Dilution Risk: Future "Subsequent Financings" at prices below the Initial Issuance Price ($10.50) will trigger conversion ratio adjustments, but the $3.75 floor limits the extent of this protection, potentially leading to greater dilution for preferred shareholders if common stock prices fall significantly below $3.75.
• Regulatory Risk: Conversion of preferred stock into common stock is subject to "Stockholder Approval" and the "Nasdaq Conversion Condition," meaning the company must be approved for initial listing on Nasdaq or another national exchange. Failure to meet these conditions could delay or prevent conversion.
• Market Volatility: The value of the preferred stock and its conversion into common stock is sensitive to the market price of the common stock, especially with the defined floor price.

Future Outlook

The filing primarily details amendments to existing merger terms and preferred stock rights, rather than providing explicit forward-looking statements or guidance on future performance. It implies future "Subsequent Financings" and the eventual "Qualified Financing" related to the merger.

Management Comments

• "Except as modified by The Fifth Amendment, the terms of the Merger Agreement remain in full force and effect."

Industry Context

This amendment is a standard procedural step in complex M&A transactions, particularly in the biotechnology and pharmaceutical sectors where financing structures often involve convertible preferred stock with anti-dilution provisions. The adjustments reflect ongoing negotiations and risk management between the merging entities and their investors, aiming to balance investor protection with operational flexibility for future capital raises.

Comparison to Industry Standards

• The inclusion of price protection provisions (anti-dilution) for convertible preferred stock is a common feature in venture capital and private equity investments in the biotech industry, designed to protect investors from dilution in subsequent financing rounds.
• Setting a "floor price" for anti-dilution adjustments, such as the $3.75 per share floor mentioned, is also a common practice. While it provides some protection, it limits the extent of that protection, indicating a negotiated compromise between the company and preferred shareholders.
• The requirement for "Stockholder Approval" and "Nasdaq Conversion Condition" for conversion is standard for ensuring compliance with exchange listing rules and corporate governance best practices, especially when significant equity issuance is involved.

Corporate Governance

Stakeholder Impact

• Preferred Shareholders (Series A & B): Receive clarified terms for conversion and redemption, including defined anti-dilution protection with a floor, and a specific redemption price for Series B. This provides more certainty but limits potential upside from full anti-dilution.
• Common Stockholders: The terms of preferred stock conversion and potential future dilutive financings will impact the common stock's outstanding share count and potentially its value. The $3.75 floor for anti-dilution could mean less dilution for common shareholders in very low-priced financings compared to an uncapped provision, but also less protection for preferred holders.
• Company Management: Gains clarity on the terms of the preferred stock, facilitating future financing decisions and the completion of the merger.

Next Steps

• Obtain Stockholder Approval for the conversion of preferred stock.
• Satisfy the Nasdaq Conversion Condition (initial listing on Nasdaq or another national securities exchange).
• Complete the Qualified Financing contemplated by the Merger Agreement.
• Potentially engage in "Subsequent Financings" which would trigger conversion ratio adjustments.
• Execute mandatory or optional redemptions of Series B Preferred Stock.

Key Dates

Recommendation

The filing provides clarity on the terms of the merger and preferred stock, which is generally positive for reducing uncertainty. However, the introduction of a floor price for anti-dilution protection for preferred shareholders could be viewed as a slight negative for those specific investors, while potentially limiting extreme dilution for common shareholders in very low-priced future financings. Without further financial details or updates on the merger's progress and the combined entity's prospects, the information is primarily procedural and does not warrant a strong buy or sell recommendation. Investors should hold and await further developments regarding the merger's completion and the operational outlook of the combined entity.

Keywords

Salarius Pharmaceuticals, Decoy Therapeutics, Merger Agreement, Preferred Stock, Convertible Stock, Series A Preferred Stock, Series B Preferred Stock, Conversion Terms, Anti-Dilution, Redemption Price, SEC Filing, 8-K, Biotechnology, Pharmaceuticals, Corporate Governance, Equity Financing